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HIV-1 Nef and the unrelated murine leukemia virus
glycoGag similarly enhance the infectivity of HIV-1
virions. We now show that the effects of Nef and gly-
coGag are similarly determined by variable regions
of HIV-1 gp120 that control Env trimer association
and neutralization sensitivity. Whereas neutraliza-
tion-sensitive X4-tropic Env proteins conferred
high responsiveness to Nef and glycoGag, particles
bearing neutralization-resistant R5-tropic Envs were
considerably less affected. The profoundly different
Nef/glycoGag responsiveness of a neutralization-
resistant and a neutralization-sensitive R5-tropic
Env could be switched by exchanging their gp120
V1/V2 regions, which also switches their neutraliza-
tion sensitivity. Within V1/V2, the same determinants
governedNef/glycoGag responsiveness and neutral-
ization sensitivity, indicating that these phenotypes
aremechanistically linked. The V1/V2 and V3 regions,
which form an apical trimer-association domain,
together determined the Nef and glycoGag respon-
siveness of an X4-tropic Env. Our results suggest
that Nef and glycoGag counteract the inactivation
of Env spikes with relatively unstable apical trimer-
association domains.INTRODUCTION
Nef is a small myristylated protein encoded by HIV-1 and other
primate lentiviruses that constitutes a crucial virulence factor.
Although not required for virus replication in cell culture, Nef is
critical for high virus loads and for the development of AIDS
in rhesus macaques infected with a pathogenic simian immuno-
deficiency virus (SIV) (Kestler et al., 1991). In humans infected
with HIV-1, defects in nef have been associated with long-term
nonprogression (Deacon et al., 1995; Kirchhoff et al., 1995).
Nef downmodulates CD4 from the surface of infected cells802 Cell Reports 5, 802–812, November 14, 2013 ª2013 The Authors(Aiken et al., 1994; Garcia and Miller, 1991; Mariani and Skow-
ronski, 1993) and also downregulates major histocompatibility
complex class I (MHC class I) molecules to protect infected cells
from cytotoxic T cells (Cohen et al., 1999; Collins et al., 1998;
Schwartz et al., 1996; Yang et al., 2002). Furthermore, Nef
modulates T cell signaling (Abraham and Fackler, 2012; Baur
et al., 1994; Du et al., 1995; Schindler et al., 2006) and inhibits
T cell migration (Stolp et al., 2009). SIV Nef proteins also antag-
onize the restriction factor BST2 (Jia et al., 2009; Zhang et al.,
2009).
Nef also enhances the intrinsic infectivity of progeny virions
by a mechanism that remains poorly understood (Aiken and
Trono, 1995; Chowers et al., 1994). It has been shown that
high levels of cell surface CD4 sequester HIV-1 Env, and that
Nef can counteract this effect by downregulating CD4 (Lama
et al., 1999). However, the CD4 downregulation and infectivity
enhancement functions of Nef can be dissociated (Goldsmith
et al., 1995). Furthermore, Nef enhances HIV-1 infectivity in cells
that lack CD4 or express a mutant CD4 that cannot be downre-
gulated (Aiken and Trono, 1995; Chowers et al., 1995; Schwartz
et al., 1995).
HIV-1 virions produced in the absence of Nef are defective at
an early step of the replication cycle (Aiken and Trono, 1995;
Miller et al., 1995; Schwartz et al., 1995). Nef is incorporated
into virions in small quantities (Pandori et al., 1996; Welker
et al., 1996), but its presence in HIV-1 particles is not sufficient
to increase their infectivity (Laguette et al., 2009). Nef does not
affect viral particle production, the processing of virion-asso-
ciated Gag or Gag-pol products, or the structure or stability of
the mature virion core (Forshey and Aiken, 2003; Miller et al.,
1995). Although some reports suggest that Nef enhances the
incorporation of Env (Day et al., 2004; Schiavoni et al., 2004),
no effect on Env incorporation was seen in other studies (Miller
et al., 1995; Pizzato et al., 2007). Although Nef may not enhance
the initial phase of virus-cell fusion (Cavrois et al., 2004; Tobiume
et al., 2003), Nef enhances the delivery of viral capsids into
the cytosol (Campbell et al., 2004; Schaeffer et al., 2001). An
effect of Nef on virus penetration is consistent with the obser-
vation that pseudotyping with pH-dependent Env proteins by-
passes the requirement for Nef (Aiken, 1997; Luo et al., 1998).
Interestingly, Nef decreases the sensitivity of HIV-1 to broadly
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Figure 1. Env Determines HIV-1 Respon-
siveness to Nef and glycoGag
(A) The Env proteins of laboratory-adapted HIV-1
strains confer high responsiveness to NefNL43.
Env/Nef and Env/Nef+ HIV-1NL43 particles
trans-complemented with the indicated Env
proteins were produced in Jurkat TAg cells, and
infectivities normalized for p24 antigen were ana-
lyzed on TZM-bl indicator target cells.
(B) The Env proteins of primary HIV-1 isolates
confer profoundly different degrees of respon-
siveness to NefNL43.
(C) Responsiveness to Nef correlates with
responsiveness to glycoGag. Env/Nef HIV-
1NL43 particles trans-complemented with the
indicated Env proteins were produced in Jurkat
TAg cells cotransfected with a small amount
(30 ng) of a vector expressing glycoMA. Bars
indicate the means of triplicate determinations
in a single experiment. Error bars indicate ± SD.
*p < 0.005 by two-tailed paired t test.
(D) Western blot shows that Nef and glycoMA do
not affect the virion association of gp41. Purified
recombinant viral particles produced in Jurkat
TAg cells by full-length Env-deficient proviruses
trans-complemented with EnvHXB2 were analyzed.
In lane 4, a Gag-deficient full-length provirus was
used.
See also Figure S1.neutralizing antibodies that target a specific region of gp41 (Lai
et al., 2011).
Recently, it emerged that the unrelated glycosylated Gag
(glycoGag) protein of Moloney murine leukemia virus (MLV)
has a comparable effect on HIV-1 infectivity as Nef (Pizzato,
2010). MLV glycoGag is an alternative Gag molecule with an
N-terminal extension that provides a transmembrane domain
and causes its insertion into the plasma membrane (Pillemer
et al., 1986). The Nef-like activity of glycoGag depends on its
cytosolic N terminus, whereas the extracellular Gag portion
is not strictly required (Pizzato, 2010). The effects of Nef and
glycoGag on HIV-1 infectivity exhibit many similarities; for
instance, they are similarly determined by the producer cell
type, and the effects of both proteins are particularly pro-
nounced in T lymphoid cells (Pizzato, 2010). Furthermore, in
an analysis of particles pseudotyped with non-HIV Env proteins,
the activities of Nef and glycoGag were similarly determined by
Env (Pizzato, 2010).
We now show that even the responsiveness of different HIV-1
Env proteins to Nef varies dramatically and correlates strictly
with their responsiveness to glycoGag. We find that responsive-
ness to Nef and glycoGag is similarly determined by variable
regions of gp120 recently reported to form a trimer-association
domain at the apex of the HIV-1 Env spike. We have also
observed a close correlation between Nef/glycoGag respon-
siveness and sensitivity to neutralization by an antibody against
the crown of the V3 loop. Together, our findings suggest
that the effects of Nef and glycoGag on HIV-1 infectivity are
determined by the quaternary conformation of the apex of the
Env trimer.CeRESULTS
HIV-1 Env Alleles Differ Significantly in Their
Responsiveness to Nef
The enhancement of HIV-1 infectivity by Nef is viral isolate
dependent (Luo and Garcia, 1996). Because Env is particularly
variable, we investigated whether Env determines themagnitude
of infectivity enhancement by Nef. Viral stocks were produced
in Jurkat cells transfected with env-defective HIV-1NL43 pro-
viruses that harbored either the wild-type (WT) NL43 nef gene
or a frameshifted version, along with expression vectors for
various HIV-1 Env alleles. The infectivities of the virus stocks,
normalized for p24 content, were compared on TZM-bl target
cells.
NefNL43 enhanced the infectivity of HIV-1NL43 particles com-
plemented with EnvNL43 by approximately 20-fold (Figure 1A).
Similarly, the infectivity of HIV-1NL43 particles pseudotyped
with EnvHXB2 was 10- to 20-fold higher in the presence of the
Nef proteins of HIV-1NL43 or of the primary isolates 97ZA012
and 93BR020 (Figure 1A; Figures S1A and S1B). HIV-1NL43 and
HIV-1HXB2 are both laboratory-adapted X4-tropic viruses, and
their Env proteins are 97% identical. However, the infectivity of
HIV-1NL43 particles pseudotyped with the more divergent Env
protein of the laboratory-adapted X4-tropic HIV-1MN strain was
also enhanced more than 10-fold by NefNL43 (Figure 1A).
We next examined the effects of Nef on the infectivities of
HIV-1NL43 particles pseudotyped with primary Envs. The infec-
tivity of HIV-1 particles bearing the R5X4-tropic Env89.6 was
strongly enhanced by NefNL43 (more than 26-fold), whereas the
infectivity of particles bearing the R5-tropic EnvADA was onlyll Reports 5, 802–812, November 14, 2013 ª2013 The Authors 803
moderately affected (less than 4-fold; Figure 1B). NefNL43,
Nef97ZA012, and Nef93BR020 had even smaller effects on the infec-
tivity of particles complemented with the R5-tropic EnvYU2 (Fig-
ures 1B, S1A, and S1B). Together, these results indicate that at
least some R5-tropic primary Envs are considerably less respon-
sive to Nef than the Env proteins of laboratory-adapted X4-tropic
strains.
Responsiveness to Nef Correlates with Responsiveness
to glycoGag
MLV glycoGag rescues the infectivity of nef-deficient HIV-1NL43
(Pizzato, 2010). To examine whether HIV-1 Env proteins differ in
their responsiveness to glycoGag, we used a fully active
N-terminal portion of glycoGag (Pizzato, 2010), here termed
glycoMA. The responsiveness of HIV-1 Env proteins to gly-
coMA, measured on TZM-bl indicator cells, correlated closely
with their responsiveness to Nef (Figure 1C). Even a small
amount of the glycoMA expression vector (30 ng) had dramatic
effects on the infectivities of env- and nef-deficient HIV-1NL43
particles trans-complemented with EnvHXB2, EnvNL43, or EnvMN
(between 65- and 296-fold). Thus, the effects of glycoMA on
particles bearing the X4-tropic Envs were even more pro-
nounced than those of Nef. Neither glycoMA nor Nef affected
viral particle production or Env incorporation (Figures 1D and
S1C), consistent with earlier reports (Pizzato, 2010; Pizzato
et al., 2007).
The glycoMA construct also strongly enhanced the infectivity
of env- and nef-deficient HIV-1NL43 particles complemented
with the R5X4-tropic Env89.6 (Figure 1C), which was similarly
responsive to Nef (Figure 1B). In marked contrast, glycoMA
had little or no effect if the R5-tropic Env proteins of the primary
ADA and YU2 isolates were used (Figure 1C), which also re-
sponded poorly to Nef (Figure 1B). Nef and glycoMA also con-
siderably enhanced the infectivity of particles bearing Env89.6,
but not of particles bearing EnvYU2, for primary monocyte-
derived macrophages (MDMs) (Figure S1D). Of note, the YU2
Env protein used in this study had a cytoplasmic domain that
was mostly derived from HIV-1HXB2. Taken together, our data
thus suggested that responsiveness to Nef and glycoMA is
determined by the ectodomain of HIV-1 Env. Consistent with
this notion, EnvHXB2 remained responsive to Nef in the absence
of a cytoplasmic domain (Figure S1E).
Responsiveness to Nef and glycoGag Is Not Determined
by Coreceptor Usage
Our results raised the possibility that coreceptor usage plays
a role in the responsiveness of HIV-1 Env proteins to Nef and
glycoGag. An alternative possibility was that there is a relation-
ship between Nef/glycoGag responsiveness and general
neutralization sensitivity. In support of this notion, all the X4-
tropic laboratory-adapted Envs that were highly responsive
to Nef and especially to glycoGag are highly susceptible to
neutralization (Mascola et al., 1996). In contrast, the R5-tropic
primary Envs that responded poorly to Nef and not at all to gly-
coGag are resistant to neutralization (Kolchinsky et al., 2001;
Krachmarov et al., 2006).
We therefore examined the effects of Nef and glycoMA on
the infectivities of particles bearing the Env proteins of the804 Cell Reports 5, 802–812, November 14, 2013 ª2013 The Authorsrelated primary isolates SF162 and JRFL, which are both R5-
tropic but differ greatly in their sensitivity to neutralization
(Pinter et al., 2004). Particles bearing these Env proteins had
comparable baseline infectivities in the absence of Nef or gly-
coMA (Figure 2A). However, only the infectivity of particles
bearing the neutralization-sensitive SF162 Env was substantially
enhanced by Nef (11-fold) and glycoMA (34-fold). In marked
contrast, Nef enhanced the infectivity of particles bearing the
neutralization-resistant JRFL Env only about 2-fold, and gly-
coMA did not enhance their infectivity at all (Figure 2A). These
results supported the notion that responsiveness to Nef and
glycoGag is related to neutralization sensitivity. Furthermore,
they excluded the possibility that responsiveness to Nef or gly-
coGag is determined by coreceptor usage because the SF162
and JRFL Env proteins both exclusively use CCR5 (Michael
et al., 1998).
The Different Responsiveness of Two R5-Tropic Envs
to Nef and glycoGag Is Determined by V1/V2
The inherent resistance of EnvJRFL to neutralization is largely
determined by variable regions 1 and 2 (V1/V2) of gp120 (Pinter
et al., 2004). These authors found that EnvJRFL becomes con-
siderably more neutralization sensitive upon replacement of its
V1/V2 region by that of neutralization-sensitive EnvSF162 (Pinter
et al., 2004). Conversely, EnvSF162 becomes considerably more
resistant to neutralization upon replacement of its V1/V2 region
by that of EnvJRFL (Pinter et al., 2004). We therefore precisely
exchanged the V1/V2 regions of the SF162 and JRFL Env pro-
teins and examined the responsiveness of the resulting SF(JR
V1/V2) and JR(SF V1/V2) chimeras to Nef and glycoMA.
The responsiveness of the SF(JR V1/V2) chimera to Nef
was considerably reduced compared to that of the parental
EnvSF162 (2.4-fold versus 11-fold), and its responsiveness to
glycoMA was dramatically lower (1.8-fold versus 39-fold) (Fig-
ure 2B). Conversely, the responsiveness of EnvJRFL to Nef was
markedly increased by replacing its V1 and V2 regions with those
of ENVSF162 (from 2.2-fold to 15-fold), and the increase in
responsiveness to glycoMA was even more pronounced (from
1.2-fold to 15-fold) (Figure 2C). Taken together with previously
published results on the neutralization sensitivity of the chimeras
(Pinter et al., 2004), these observations implied that neutraliza-
tion sensitivity and responsiveness to Nef or glycoMA can be
switched simultaneously.
Exchange of V2 Region Is Sufficient to Switch
Responsiveness of SF162 and JRFL Env to Nef
and glycoGag
The V1/V2 region comprises a single topological entity that folds
as four antiparallel b strands (McLellan et al., 2011). Strands A
and B flank the highly variable V1 loop. Strands C and D, both
located entirely within the V2 region, are connected by the less
variable V2 loop (McLellan et al., 2011).
To examine the individual contribution of the V1 and V2 re-
gions to the Nef/glycoGag responsiveness of EnvSF162 and
EnvJRFL, we generated chimeric Envs in which only the V1
or the V2 region was exchanged (Figure 3). The JR(SF V1)
chimeric Env remained as poorly responsive to Nef as EnvJRFL
and also remained entirely unresponsive to glycoMA (Figure 3A).
A0
5
10
15
20
25
30
35
40
SF162 JRFL
Vector glycoMA
0
1
2
3
4
5
6
7
SF162 JRFL
In
fe
ct
iv
ity
 (m
U
β-
G
al
/n
g
p2
4)
Nef- Nef+
SF162
JRFL
0
1
2
3
4
5
6
7
SF162 SF (JR 
V1/V2)
In
fe
ct
iv
ity
 (m
U
β-
G
al
/n
g
p2
4)
Nef- Nef+
0
10
20
30
40
50
SF162 SF (JR 
V1/V2)
Vector glycoMA
B
0
1
2
3
4
5
JRFL JR (SF 
V1/V2)
In
fe
ct
iv
ity
 (m
U
β-
G
al
/n
g
p2
4)
Nef- Nef+
0
2
4
6
8
10
12
14
JRFL JR (SF 
V1/V2)
Vector glycoMA
C JRFL
JR(SF V1/V2)
V1 V2
SF162
SF(JR V1/V2)
V1 V2
Env: Env:
Env: Env:
Env: Env:
*
*
*
* *
*
*
*
Figure 2. The Differential Nef/glycoGag Responsiveness of Two
Related X5-Tropic Envs Is Determined by V1/V2
(A) EnvSF162 confers high responsiveness to both Nef and glycoMA, whereas
EnvJRFL confers poor responsiveness to Nef and resistance to glycoMA.
(B) EnvSF162 becomes poorly responsive to Nef and resistant to glycoMA upon
replacement of its V1/V2 region by that of EnvJRFL.
(C) EnvJRFL becomes highly responsive to Nef and glycoMA upon replace-
ment of its V1/V2 region by that of EnvSF162. Bars indicate the means of
triplicate determinations in a single experiment. Error bars indicate ± SD.
*p < 0.005.
CeIn striking contrast, the JR(SF V2) chimeric Env was nearly
as highly responsive to both Nef and glycoMA as EnvSF162
(Figure 3A).
We also examined the sensitivity of the JR(SF V2) chimera to
cold inactivation, which is determined by the major variable
regions of Env (Medjahed et al., 2013). While EnvJRFL was resis-
tant to cold, the JR(SF V2) chimera was moderately sensitive.
However, the level of sensitivity was not significantly influenced
by Nef or glycoMA (Figure S2).
Next, we generated the reciprocal Env chimera in which the
V2 region of the highly Nef/glycoGag-responsive EnvSF162 was
precisely replaced by that of the poorly responsive EnvJRFL.
Despite being identical to EnvSF162 except for V2, the SF(JR
V2) chimeric Env closely resembled EnvJRFL in its poor response
to Nef and unresponsiveness to glycoMA (Figure 3B). These
results establish that the V2 region determines the different
responsiveness of EnvSF162 and EnvJRFL to Nef and glycoGag,
whereas the V1 region plays no significant role.
The B-C Hairpin in V2 Governs the Nef and glycoGag
Responsiveness of JRFL Env
Within the V2 region, EnvSF162 and EnvJRFL differ at eight posi-
tions (Figure 4A). To examine which of these differences deter-
mine responsiveness to Nef and/or glycoGag, we generated
EnvJRFL mutants that harbor either strand B, strand C, or the
V2 loop together with strand D of EnvSF162, yielding the JR(SF
B strand), JR(SF C strand), and JR(SF V2/D strand) Envs,
respectively. None of these mutants was significantly more
responsive to Nef or glycoMA than the poorly responsive
parental EnvJRFL (Figure 4B). We also examined a versions of
EnvJRFL that harbored both strand B and strand C of EnvSF162,
denoted JR(SF B-C hairpin), and a version of the JR(SF C
strand) chimera with an N160K mutation in strand B, denoted
JR/N160K(SF C strand). The N160K mutation eliminates an
N-linked glycosylation site that is present in EnvJRFL but absent
from EnvSF162 (Pinter et al., 2004). The JR(SF B-C hairpin) and
JR/N160K(SF C strand) chimeras exhibited robust responsive-
ness to Nef and glycoMA (Figures 4B and 4C). These results
indicate that differences in the B-C hairpin largely account for
the differences in responsiveness of EnvSF162 and EnvJRFL to
Nef and glycoGag.
Nef/glycoGag Responsiveness Correlates Closely
with Sensitivity to Neutralization by a V3
Monoclonal Antibody
The neutralization phenotypes of EnvSF162 and EnvJRFL could be
switched by swapping their V1/V2 regions, which had particu-
larly pronounced effects on sensitivity to neutralization by V3-
specific monoclonal antibodies (mAbs) such as mAb 447-52D
(Pinter et al., 2004). Because exchanging the V1/V2 regions of
EnvSF162 and EnvJRFL also switches their responsiveness to
Nef and glycoGag, we further examined the relationship be-
tween Nef/glycoGag responsiveness and sensitivity to neutrali-
zation by mAb 447-52D.
Irrespective of whether Nef was present or absent during
virus production, viral particles bearing EnvJRFL were resistant
to 447-52D, whereas particles bearing the JR(SF V1/V2) Env
chimera were potently neutralized (Figure 5A). Interestingly, thell Reports 5, 802–812, November 14, 2013 ª2013 The Authors 805
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Figure 3. Replacement of V2 Region Is
Sufficient to Switch Nef and glycoGag
Responsiveness
(A) EnvJRFL becomes as highly responsive to Nef
and glycoMA as EnvSF162 upon replacement of its
V2 but not of its V1 domain by that of EnvSF162.
(B) EnvSF162 becomes as poorly responsive to
Nef and glycoMA as EnvJRFL upon replacement
of its V2 region by the corresponding JRFL
sequence. Bars indicate the means of triplicate
determinations in a single experiment. Error bars
indicate ± SD. *p < 0.005.
See also Figure S2.JR(SF V1) chimera was as resistant to 447-52D as the parental
EnvJRFL (Figure 5B), whereas the JR(SF V2) chimera was nearly
as potently neutralized as the JR(SF V1/V2) chimera (Figure 5C).
Thus, the SF162-derived V2 region conferred both Nef/glycoGag
responsiveness and neutralization sensitivity, whereas the
SF162-derived V1 region conferred neither.
As recently reported (Lai et al., 2011), Nef reduced the sensi-
tivity of particles bearing EnvJRFL to neutralization by mAb 2F5
(Figure S3), which targets the membrane-proximal external re-
gion (MPER) of gp41 (Purtscher et al., 1994). Nef also partially
protected the JR(SF V1) chimera, which exhibited a comparable
susceptibility to 2F5 as EnvJRFL (Figure S3). However, Nef did
not significantly protect the JR(SF V1/V2) and JR(SF V2) chi-
meras, which were more susceptible to 2F5 than was EnvJRFL
(Figure S3).
We also examined the effects of 447-52D on the JR(SF B
strand) and JR(SF C strand) Env chimeras, which resemble the
parental EnvJRFL in their poor responsiveness to Nef and glyco-
Gag. Both chimeras were nearly as resistant to 447-52D as the
parental EnvJRFL (Figure 6). In contrast, the Nef- and glycoGag-
responsive JR(SF B-C hairpin) and JR/N160K(SF C strand)
chimeras were clearly neutralized by 447-52D (Figure 6). Thus,
determinants within the SF162-derived strands B and C
together, but not the individual strands, simultaneously con-
ferred significant Nef/glycoGag responsiveness and neutraliza-
tion sensitivity.806 Cell Reports 5, 802–812, November 14, 2013 ª2013 The AuthorsV1/V2 and V3 Together Determine
the Nef and glycoGag
Responsiveness of a Laboratory-
Adapted Env
EnvSF162 and EnvJRFL are both R5-tropic
primary isolates (Michael et al., 1998).
To examine whether the V1/V2 region
also governs the Nef and glycoGag
responsiveness of a laboratory-adapted
X4-tropic Env, we used a previously
described version of the highly Nef- and
glycoGag-responsive EnvHXB2 that has
the V1/V2 region precisely replaced by
that of the poorly Nef- and glycoGag-
responsive EnvYU2 (Figure 7A) (Sullivan
et al., 1998). Compared to the parental
EnvHXB2, the HX(YU V1/V2) chimeraexhibited no decreased responsiveness to Nef (Figure 7B) or
glycoMA (Figure 7C). Thus, the transfer of the V1/V2 region by
itself did not confer a YU2-like phenotype.
Whereas EnvSF162 and EnvJRFL have similar V3 regions,
EnvHXB2 and EnvYU2 differ substantially in V3. Therefore, we
examined the phenotype of another previously described Env
chimera (Sullivan et al., 1998), here called HX(YU V3), that is
identical to EnvHXB2 except that the V3 region is from EnvYU2
(Figure 7A). In contrast to the parental EnvHXB2, the HX(YU V3)
chimeric Env can use CCR5 as a coreceptor (Choe et al.,
1996). In our hands, the presence of the YU2 V3 region in the
EnvHXB2 background conferred a dramatically increased base-
line infectivity for TZM-bl cells, which have high levels of CCR5
(Figures 7B and 7C). Although to a lesser degree than the
parental EnvHXB2, the HX(YU V3) Env chimera clearly remained
responsive to Nef (Figure 7B) and glycoMA (Figure 7C). These
results suggested that the YU2 V3 region alone mitigated the
effects of Nef and glycoMA, albeit to a limited extent.
A recent cryo-EM structure indicates that the V1/V2 and V3
regions of gp120 together form a trimer-association domain at
the apex of the unliganded Env spike (Mao et al., 2012). Based
on this model, we examined the possibility that the V1/V2 and
V3 regions together determine the effects of Nef and glycoGag
on virus infectivity. We found that a chimera designated HX(YU
V1/V2/V3), which harbors both the YU2 V1/V2 and YU2 V3
regions in the EnvHXB2 background (Figure 7A), exhibited a
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Figure 4. B-C Hairpin of V2 Region Governs
Nef and glycoGag Responsiveness of
EnvJRFL
(A) Alignment of the V2 regions of EnvSF162 and
EnvJRFL is shown. Identical residues are indicated
by hyphens, and b strands by lines above the
alignment (McLellan et al., 2011). The arrow in-
dicates were sequences were joined to generate
the JR(SF B–C hairpin) and JR (SF V2/D strand)
chimeras.
(B) The entire B-C hairpin of EnvSF162 confers an
SF162-like Nef and glycoGag responsiveness to
EnvJRFL, whereas individual strands from the
SF162 V2 region do not.
(C) The N160K mutation together with strand C
of Env162 confer Nef and glycoGag responsive-
ness to EnvJRFL. Error bars indicate ± SD. *p <
0.005.baseline infectivity that was only moderately higher than that
of the parental EnvHXB2. However, in contrast to the highly
responsive EnvHXB2, the HX(YU V1/V2/V3) chimera was poorly
responsive to Nef (less than 2-fold; Figure 7B) and completely
unresponsive to glycoMA (Figure 7C). Together, these results
support the notion that Nef and glycoGag responsiveness
are governed by the trimer-association domain composed of
V1/V2 and V3.
DISCUSSION
This study shows that the effects of Nef and glycoGag on the
infectivity of HIV-1 virions are determined by the V1/V2 and V3
regions of gp120. Recent cryo-EM structures indicate that these
variable regions are near the apex of the Env trimer (Liu et al.,
2008; White et al., 2010) and together form a trimer-association
domain that stabilizes the unliganded Env spike (Mao et al.,
2012). Our data suggest that Nef and glycoGag responsiveness
is controlled by the architecture of this trimer-association
domain, which has been proposed to be metastable (Mao
et al., 2012). In support of this model, we have observed a close
relationship between responsiveness to Nef or glycoGag and
sensitivity to neutralization by a V3 mAb.Cell Reports 5, 802–812, NOur data show that the V1/V2 region of
gp120 determines the markedly different
Nef and glycoGag responsiveness of
two related R5-tropic Envs that have
similar V3 regions. The highly responsive
EnvSF162 became as unresponsive as
EnvJRFL in the presence of the JRFL V1/
V2 region. Conversely, EnvJRFL became
highly responsive in the presence of the
SF162 V1/V2 region. Interestingly, the
V1/V2 region also determines the high
neutralization sensitivity of EnvSF162
and the neutralization resistance of
EnvJRFL (Pinter et al., 2004). The differen-
tial sensitivities of these Env proteins
to neutralization by antibodies targetingV3 or other sites on gp120 can be switched by exchanging
their V1/V2 regions (Pinter et al., 2004), consistent with the notion
that V1/V2 shields the V3 region and other functionally important
sites from recognition by antibodies (Pantophlet and Burton,
2006).
The V1/V2 region is not strictly required for virus replication
(Cao et al., 1997; Johnson et al., 2002; Saunders et al., 2005),
but nevertheless plays an important role in holding together
unliganded Env trimers (Hu et al., 2011; Liu et al., 2008). The
V1 and V2 regions are proposed to contact each other at the
apex of the trimer in the unliganded state and to move away
upon CD4 binding (Liu et al., 2008). It was recently shown that
the V1/V2 region, together with the V3 region, restrains the
tendency of HIV-1 Env spikes to spontaneously assume the
neutralization-sensitive CD4-bound conformation (Kwon et al.,
2012). Consistent with this view, a recent cryo-EM structure of
the unliganded EnvJRFL trimer indicates that V1/V2 together
with V3 form an apical trimer-association domain that restricts
antibody access to conserved regions within the interior of the
cage-like structure (Mao et al., 2012). Accordingly, the globally
increased neutralization sensitivity of EnvJRFL in the presence
of the SF162 V1/V2 region suggests a propensity to assume a
more open quaternary conformation.ovember 14, 2013 ª2013 The Authors 807
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Figure 5. SF162 V2 Region Confers Sensi-
tivity to Neutralization by a V3 mAb
(A) Neutralization curves confirming that the
replacement of the V1/V2 region of EnvJRFL by
that of EnvSF162 confers sensitivity to neutralization
by 447-52D are shown. Pseudotyped viruses
were produced in the presence or absence of Nef,
as indicated.
(B) EnvJRFL remains resistant to 447-52D in the
presence of the EnvSF162 V1 region.
(C) Replacement of the V2 region alone is sufficient
to confer sensitivity to neutralization by 447-52D.
See also Figure S3.There is evidence that within V1/V2 it is primarily the V2 region
that confers protection against neutralization (O’Rourke et al.,
2010, 2012; Stamatatos and Cheng-Mayer, 1998; Watkins
et al., 2011). Similarly, we find that the transfer of the V2 region,
but not of the V1 region, from EnvSF162 to EnvJRFL is sufficient to
confer sensitivity to neutralization by mAb 447-52, which recog-
nizes an epitope at the tip of the V3 loop (Stanfield et al., 2004).
The transfer of the V2 region also increased the sensitivity of
EnvJRFL to the MPER mAb 2F5, particularly in the presence of
Nef, which renders WT EnvJRFL resistant to 2F5 (Lai et al.,
2011). Furthermore, the transfer of the V2 region conferred sensi-
tivity to cold inactivation, which has been linked to the propensity
to sample the CD4-bound conformation (Kassa et al., 2009).
Interestingly, the transfer of the V2 region was also sufficient to
confer an SF162-like responsiveness to Nef and glycoGag.
Together, these findings suggest that Nef/glycoGag responsive-
ness is related to the propensity of Env to undergo conforma-808 Cell Reports 5, 802–812, November 14, 2013 ª2013 The Authorstional transitions, a property that has
been called ‘‘intrinsic reactivity’’ (Haim
et al., 2011).
The V2 region contains a conserved tri-
peptide reported to serve as a binding
site for integrin a4b7 (Arthos et al., 2008).
However, a different region of V2 ac-
counted for the differential Nef/glycoGag
responsiveness of EnvSF162 and EnvJRFL,
namely, the tip of the B-C hairpin formed
by the N terminus of V2. Modifications
in the EnvJRFL B-C hairpin that con-
ferred Nef/glycoGag responsiveness
also conferred sensitivity to neutralization
by 447-52D, supporting the notion that
these phenotypes are related.
To transfer the Nef/glycoGag resis-
tance of a primary R5-tropic Env to a
laboratory-adapted X4-tropic Env with a
highly divergent V3 region, it was neces-
sary to replace both the V1/V2 and V3
regions of gp120. This result supports
the model that Nef and glycoGag respon-
siveness reflect the configuration of
the recently reported trimer-association
domain at the membrane-distal apex ofthe spike (Mao et al., 2012). The cryo-EM structure of the unli-
ganded EnvJRFL trimer indicates that the V1/V2 and V3 variable
regions of this neutralization-resistant isolate together form a
six-way junction at the gp120 interfaces (Mao et al., 2012).
Thus, the simultaneous transfer of the V1/V2 and V3 regions of
the highly neutralization-resistant EnvYU2 to the neutralization-
sensitive EnvHXB2 may lead to a more stable six-way junction.
It is noteworthy in this regard that the simultaneous transfer of
the YU2 V1/V2 and V3 regions confers a higher degree of neutral-
ization resistance to EnvHXB2 than does the transfer of either
region alone (Sullivan et al., 1998).
In one study, Nef and a sorting signal in the Env cytoplasmic
tail each enhanced the efficiency of HIV-1 entry independently
of the Env content of virions (Day et al., 2004). It has therefore
been proposed that the sorting signal targets the trafficking of
Env to a compartment optimal for the assembly of infectious
virions, and that Nef modifies this compartment (Day et al.,
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Figure 6. SF162 B-C Hairpin Confers Sensi-
tivity to 447-52D
The neutralization sensitivity of particles pseudo-
typed with the indicated Env proteins in the pres-
ence of Nef was determined.2004). It is conceivable that the fusogenicity of relatively unstable
Env complexes benefits disproportionately from assembly in
such a compartment. Interestingly, the enhancement of HIV-1
infectivity by Nef correlates with Nef-induced alterations of
the endocytic recycling compartment (Madrid et al., 2005).
These widespread alterations likely involve endosome-associ-
ated clathrin adaptor complexes (Madrid et al., 2005), providing
a possible basis for the observation that the effect of Nef on
HIV-1 infectivity depends on clathrin (Pizzato et al., 2007). Alter-
natively, Nef may affect the clathrin-mediated endocytosis
or trafficking of a specific host factor that disproportionately
influences the ability of relatively unstable Env trimers tomaintain
the high potential energy necessary for virus-cell fusion (Med-
jahed et al., 2013).
It has been reported that Nef does not affect the fusion of HIV-1
virionswith target cells (Cavrois et al., 2004; Tobiumeet al., 2003).
However, in another study that employed a similar assay Nef-
deficient viruses exhibited a 50% reduction in viral entry (Day
et al., 2004). Although the defect in entry did not fully explain
the much larger defect in infectivity, it was suggested that the
highly concentrated inocula needed for the entry assay may
have been responsible for the difference (Day et al., 2004). Our
finding that gp120 variable regions determine the effect of Nef
on HIV-1 infectivity supports the notion that Nef enhances entry.
Our results suggest that primary Envs generally do not
possess the dramatic Nef responsiveness of laboratory-adapted
Envs. However, primary Envs differ considerably in their intrinsic
reactivities (Haim et al., 2011), and those relatively prone to
conformational transitions upon stimulation may exhibit sub-
stantial Nef/glycoGag responsiveness.Cell Reports 5, 802–812, NEXPERIMENTAL PROCEDURES
Plasmids
The env-deficient HIV-1 proviruses HXB/Env/
Nef+ and HXB/Env/Nef have been described
(Dorfman et al., 2002), as have the vectors
expressing Nef97ZA012 and Nef93BR020 (Pizzato
et al., 2007). The vector expressing glycoMA
(pBJ5-glycoMA) was made by inserting nt 360–
926 of Moloney MLV (J02255) into pBJ5 after a
Kozak sequence and an ATG initiation codon.
The MLV sequence is followed by a sequence
encoding an HA tag and a stop codon. Vectors
expressing EnvSF162 and EnvJRFL from pSVIIIenv
have been described (Peters et al., 2004). V1/V2
chimeras were made by exchanging DraIII-StuI
fragments between these vectors as described
(Pinter et al., 2004). The V1/V2 chimeras
were used to generate V1 and V2 chimeras by
PCR-based cloning. Intra-V2 chimeras were
made by PCR-based cloning or by site-directed
mutagenesis. All these chimeras were expressed
from the same vector (pSVIIIenv). The pEnvHXB
and pEnvHXBDCT plasmids are pBJ5-basedexpression vectors for WT and cytoplasmic tail-deleted EnvHXB2 (Reil et al.,
1998). A pBJ5-based expression vector for EnvYU2 was generated by replac-
ing the KpnI-XhoI fragment of pEnvHXB (nt 6347–8897 of HIV-1HXB2) with the
corresponding fragment from a pSVIIIenv-based EnvYU2 expression vector
(Sullivan et al., 1998). In the same manner, pBJ5-based expression vectors
for EnvHXB2 containing the YU2 V1/V2 region, the YU2 V3 region, or the
YU2 V1/V2 region together with the YU2 V3 region were made by transferring
KpnI-XhoI fragments from pSVIIIenv-based expression vectors (Sullivan
et al., 1998) into pEnvHXB.
Analysis of Virus Infectivity
Pseudovirions capable of a single round of replication were produced by
transfecting Jurkat TAg cells with lipofectamine 2000 (Invitrogen). To
examine the effects of Nef on HIV-1 infectivity, 1 mg of HXB/Env/Nef+ or
HXB/Env/Nef was transfected along with 100 ng of a pSVIIIenv-based
Env expression vector. To examine the effects of glycoGag, 1 mg HXB/
Env/Nef was transfected along with 100 ng of a pSVIIIenv-based Env
expression vector and 30 ng of pBJ5-glycoMA or the empty vector. Addition-
ally, an HIV-1 vector expressing GFP was cotransfected for macrophage in-
fections. For the experiment shown in Figure 7, pBJ5-based Env expression
vectors (0.5 mg) were used. Supernatants containing progeny virions were
harvested 2 days post transfection, clarified by low-speed centrifugation,
filtered through 0.45 mm pore filters, and then used immediately to infect
TZM-bl indicator cells in triplicate in T25 flasks. Alternatively, primary human
MDM prepared as described (Peters et al., 2004) were used as target cells
because of their relative susceptibility to single-round infection with 89.6
and YU2 Env pseudovirions. Aliquots of the virus stocks were frozen for
p24 antigen quantitation by a standard ELISA. Three days post infection,
TZM-bl indicator cells were lysed in 400 ml reporter lysis buffer (Promega),
and b-gal activity was measured according to the manufacturer’s instruc-
tions. Infected MDM were quantified by counting GFP-positive cells in five
random fields under a fluorescent microscope equipped with an X20 objec-
tive. Values were normalized for the amount of p24 antigen present in the
supernatants used for infection.ovember 14, 2013 ª2013 The Authors 809
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Figure 7. V1/V2 and V3 Regions Together Determine Nef and gly-
coGag Responsiveness of a Laboratory-Adapted Env
(A) Schematic illustration of the Env proteins examined is shown.
(B) EnvHXB2 becomes poorly responsive to Nef only after the simultaneous
replacement of its V1/V2 and V3 regions by those of EnvYU2.
(C) Responsiveness of the Env chimeras to glycoMA correlates with their
responsiveness to Nef. Bars indicate the means of triplicate determinations in
a single experiment. Error bars indicate ± SD. *p < 0.005.Neutralization Assays
Pseudovirions produced in 293T cells transfected with HXB/Env/Nef+
or HXB/Env/Nef and a pSVIIIenv-based Env expression vector were
quantified by p24 antigen ELISA. Pseudovirions equivalent to 60 ng p24
were then incubated in a total volume of 200 ml in the presence of mAb
447-52D at 0.016, 0.08, 0.4, and 2 mg/ml or of mAb 2F5 at 0.24, 1.2, 6,
and 30 mg/ml. After 1 hr of incubation at 37C, the mixture was added
to TZM-bl indicator cells that had been seeded into T25 flasks the day
before. Three days later, the indicator cells were lysed and analyzed for
b-gal activity.810 Cell Reports 5, 802–812, November 14, 2013 ª2013 The AuthorsSUPPLEMENTAL INFORMATION
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